



ASX Announcement
27 August 2019

**IDT SECURES ITS FIRST MEDICINAL CANNABIS MANUFACTURING
PERMIT FROM THE OFFICE OF DRUG CONTROL**

IDT Australia Limited (**ASX: IDT**) is pleased to announce that the Department of Health – Office of Drug Control has granted the Company its first Medicinal Cannabis Manufacturing Permit under the *Narcotic Drugs Act 1967*.

The Permit allows IDT to manufacture and store cannabis extract at the IDT premises licensed by the Office of Drug Control in quantities specified by the Permit.

“IDT has a long history of Manufacturing both Active Pharmaceutical Ingredients (API’s) and Finished Dosage Forms.” said Jim Sosis IDT’s Vice President of Operations Supply and Infrastructure “This permit compliments IDT’s Good Manufacturing Practice (GMP) licenses, our Schedule 8 and 9 Poisons Licensure, along with our Medicinal Cannabis Manufacturing Licence; and paves the way for IDT to ramp-up our activities in GMP medicinal cannabis manufacturing.”

ENDS

For further information please contact:
IDT Australia Limited
Dr David Sparling – Chief Executive Officer
0417 721 972

About IDT

IDT (ASX:IDT) is a public Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. It has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT’s facilities are fully cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.